Lundbeck Rebuilds Neurology Pipeline with Abide Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)

Published: 9 May-2019

DOI: 10.3833/pdr.v2019.i5.2421     ISSN: 1756-7874

Section: Mergers & Acquisitions



Lundbeck has moved to expand its reach in the neurology market with the acquisition of Abide Therapeutics, a company focused on targeting enzymes of the serine hydrolase class, for a deal value of up to US$400 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details